Jane Gross
Directeur/Membre du Conseil chez ATYR PHARMA, INC.
Fortune : 10 380 $ au 31/05/2024
Profil
Dr. Jane A.
Gross is an Independent Director at BriaCell Therapeutics Corp., an Independent Director at aTyr Pharma, Inc. and an Independent Director at BriaPro Therapeutics Corp.
She is on the Board of Directors at BriaCell Therapeutics Corp., aTyr Pharma, Inc., Washington Biotechnology & Biomedical Association and BriaPro Therapeutics Corp.
Dr. Gross was previously employed as a Chief Scientific Officer & Senior Vice President by Aptevo Therapeutics, Inc., a VP-Applied Research & Non-Clinical Development by Emergent BioSolutions, Inc., and a Vice President-Immunology Research by ZymoGenetics, Inc. She received her doctorate degree from the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ATYR PHARMA, INC.
0,01% | 22/05/2024 | 6 000 ( 0,01% ) | 10 380 $ | 31/05/2024 |
| 20/12/2023 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Jane Gross
| Sociétés | Poste | Début |
|---|---|---|
| ATYR PHARMA, INC. | Directeur/Membre du Conseil | 28/06/2019 |
| BRIACELL THERAPEUTICS CORP. | Directeur/Membre du Conseil | 01/11/2021 |
| Washington Biotechnology & Biomedical Association | Directeur/Membre du Conseil | - |
BriaPro Therapeutics Corp.
 BriaPro Therapeutics Corp. Pharmaceuticals: MajorHealth Technology BriaPro Therapeutics Corp. a clinical stage biotechnology company focuses on the development of BriaTILsRx™ and PKCd inhibitors for multiple indications including cancer. The company was founded on May 15, 2023 and is headquartered West Vancouver, Canada. | Directeur/Membre du Conseil | - |
Anciens postes connus de Jane Gross
| Sociétés | Poste | Fin |
|---|---|---|
| APTEVO THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 14/09/2021 |
| EMERGENT BIOSOLUTIONS INC. | Corporate Officer/Principal | 01/08/2016 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | 01/06/2010 |
Formation de Jane Gross
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| APTEVO THERAPEUTICS INC. | Health Technology |
| ATYR PHARMA, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| BRIACELL THERAPEUTICS CORP. | Health Technology |
| Entreprise privées | 3 |
|---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
| Washington Biotechnology & Biomedical Association | |
BriaPro Therapeutics Corp.
BriaPro Therapeutics Corp. Pharmaceuticals: MajorHealth Technology BriaPro Therapeutics Corp. a clinical stage biotechnology company focuses on the development of BriaTILsRx™ and PKCd inhibitors for multiple indications including cancer. The company was founded on May 15, 2023 and is headquartered West Vancouver, Canada. | Health Technology |
